Rebecca S. Heist - Researcher Profile

Publications

4 shown

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Scott Gettinger , Leora Horn , Leena Gandhi +26 more

Purpose Programmed death 1 is an immune checkpoint that suppresses antitumor immunity. Nivolumab, a fully human immunoglobulin G4 programmed death 1 immune checkpoint inhibitor ...

2015 Journal of Clinical Oncology 1178 citations

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Lecia V. Sequist , Belinda A. Waltman , Dora Dias‐Santagata +19 more

Lung cancers undergo dynamic genetic and histological changes upon developing resistance to EGFR inhibitors.

2011 Science Translational Medicine 3483 citations

Lung cancer

Alesha Thai , Benjamin Solomon , Lecia V. Sequist +2 more

Lung cancer is one of the most frequently diagnosed cancers and the leading cause of cancer-related deaths worldwide with an estimated 2 million new cases and 1·76 million ...

2021 The Lancet 2256 citations

Code Status Documentation in the Outpatient Electronic Medical Records of Patients with Metastatic Cancer

Jennifer S. Temel , Joseph A. Greer , Sonal Admane +5 more

2009 Journal of General Internal Medicine 80 citations

Frequent Co-Authors

Researcher Info

h-index: 4
Publications: 4
Citations: 6,997
Institution: Dana-Farber Cancer Institute

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-7397-2009

Impact Metrics

h-index 4

h-index: Number of publications with at least h citations each.